» Articles » PMID: 20597679

The Prevalence of Fluoroquinolone Resistance Mechanisms in Colonizing Escherichia Coli Isolates Recovered from Hospitalized Patients

Overview
Journal Clin Infect Dis
Date 2010 Jul 6
PMID 20597679
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Fluoroquinolones are the most commonly prescribed antimicrobials. The epidemiology of fecal colonization with Escherichia coli demonstrating reduced susceptibility to fluoroquinolones remains unclear.

Methods: During a 3-year period (15 September 2004 through 19 October 2007), all patients hospitalized for >3 days were approached for fecal sampling. All E. coli isolates with reduced susceptibility to fluoroquinolones (minimum inhibitory concentration [MIC] of levofloxacin, 0.125 microg/mL) were identified. We characterized gyrA and parC mutations and organic solvent tolerance. Isolates were compared using pulsed-field gel electrophoresis.

Results: Of 353 patients colonized with E. coli demonstrating reduced fluoroquinolone susceptibility, 300 (85.0%) had 1 gyrA mutation, 161 (45.6%) had 1 parC mutation, and 171 (48.6%) demonstrated organic solvent tolerance. The mean numbers of total mutations (ie, gyrA and parC) for E. coli isolates with a levofloxacin MIC of 8 microg/mL versus <8.0 microg/mL were 2.70 and 0.82 (P < .001). Of the 136 E. coli isolates with a levofloxacin MIC of 8 microg/mL, 90 (66.2%) demonstrated a nalidixic acid MIC of 16 microg/mL. Significant differences were found over time in the proportion of E. coli isolates demonstrating gyrA mutation, parC mutation, and organic solvent tolerance. There was little evidence of clonal spread of isolates. Conclusions. Gastrointestinal tract colonization with E. coli demonstrating reduced susceptibility to levofloxacin is common. Although 40% of study isolates exhibited a levofloxacin MIC of <8 microg/mL (and would thus be missed by current Clinical and Laboratory Standards Institute breakpoints), nalidixic acid resistance may be a useful marker for detection of such isolates. Significant temporal changes occurred in the proportion of isolates exhibiting various resistance mechanisms.

Citing Articles

Role of the Water-Metal Ion Bridge in Quinolone Interactions with Gyrase.

Carter H, Wildman B, Schwanz H, Kerns R, Aldred K Int J Mol Sci. 2023; 24(3).

PMID: 36769202 PMC: 9917921. DOI: 10.3390/ijms24032879.


Approaches for Mitigating Microbial Biofilm-Related Drug Resistance: A Focus on Micro- and Nanotechnologies.

Rao H, Choo S, Rajeswari Mahalingam S, Adisuri D, Madhavan P, Md Akim A Molecules. 2021; 26(7).

PMID: 33810292 PMC: 8036581. DOI: 10.3390/molecules26071870.


Don't Get Wound Up: Revised Fluoroquinolone Breakpoints for Enterobacteriaceae and Pseudomonas aeruginosa.

Van T, Minejima E, Chiu C, Butler-Wu S J Clin Microbiol. 2019; 57(7).

PMID: 31043468 PMC: 6595448. DOI: 10.1128/JCM.02072-18.


High fluoroquinolone MIC is associated with fluoroquinolone treatment failure in urinary tract infections caused by fluoroquinolone susceptible Escherichia coli.

Rattanaumpawan P, Nachamkin I, Bilker W, Roy J, Metlay J, Zaoutis T Ann Clin Microbiol Antimicrob. 2017; 16(1):25.

PMID: 28390438 PMC: 5385084. DOI: 10.1186/s12941-017-0202-4.


Rectal Culture-Guided Targeted Antimicrobial Prophylaxis Reduces the Incidence of Post-Operative Infectious Complications in Men at High Risk for Infections Submitted to Transrectal Ultrasound Prostate Biopsy - Results of a Cross-Sectional Study.

Boeri L, Fontana M, Gallioli A, Zanetti S, Catellani M, Longo F PLoS One. 2017; 12(1):e0170319.

PMID: 28122053 PMC: 5266328. DOI: 10.1371/journal.pone.0170319.


References
1.
Neuhauser M, Weinstein R, Rydman R, Danziger L, Karam G, Quinn J . Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA. 2003; 289(7):885-8. DOI: 10.1001/jama.289.7.885. View

2.
Jacoby G . Mechanisms of resistance to quinolones. Clin Infect Dis. 2005; 41 Suppl 2:S120-6. DOI: 10.1086/428052. View

3.
Gautom R . Rapid pulsed-field gel electrophoresis protocol for typing of Escherichia coli O157:H7 and other gram-negative organisms in 1 day. J Clin Microbiol. 1997; 35(11):2977-80. PMC: 230100. DOI: 10.1128/jcm.35.11.2977-2980.1997. View

4.
Oethinger M, Kern W, Jellen-Ritter A, McMurry L, Levy S . Ineffectiveness of topoisomerase mutations in mediating clinically significant fluoroquinolone resistance in Escherichia coli in the absence of the AcrAB efflux pump. Antimicrob Agents Chemother. 1999; 44(1):10-3. PMC: 89620. DOI: 10.1128/AAC.44.1.10-13.2000. View

5.
Okusu H, Ma D, Nikaido H . AcrAB efflux pump plays a major role in the antibiotic resistance phenotype of Escherichia coli multiple-antibiotic-resistance (Mar) mutants. J Bacteriol. 1996; 178(1):306-8. PMC: 177656. DOI: 10.1128/jb.178.1.306-308.1996. View